So, the blog was finally able to listen to the Amyris earnings webcast on November 1 and heard the confirmation that the company did buy Draths’ assets although no amount was disclosed. Draths, according to Amyris, has been working with E.coli on bio-monomers production but Amyris intends to switch over to using yeast.
Draths’ technologies in producing biopolymers such as biobased terephthalic acid (TPA) for PET manufacture and biobased polyamides and polyurethane represent over $50bn opportunity in several specific markets, according to Amyris.
“Draths’ technology will be integrated really well in our current R&D activities,” says Amyris. “Several very large companies are very interested in the Draths platform and we expect to have collaborations in place in the next several quarters.”
And before the blog forgets the heading of this post, Amyris also announced its partnership with consumer product company Method to collaborate and develop ingredients such as surfactants and solvents based on Amyris’ Biofene molecule for household and personal care products. If readers recall, Amyris also has collaborations with Procter & Gamble although specific products were not disclosed on this partnership.
Amyris said during the conference call that it does not expect to commercially scale-up farnesene production for both Method and P&G’s use until 2013. The company expects to deliver commercial products in 2012 to five markets: diesel (Total JV), lubricants (Novvi), polymers (M&G), flavors and fragrances (Firmenich, Givaudan) and Cosmetics (Nikkol).
Speaking of production, Amyris also said that it has received final approval from the Brazilian Development Bank (BNDES) for a R$22m ($12.6m) project financing facility for Amyris’ first industrial-scale production facility in Piracicaba, Sao Paulo.
Amyris is already producing farnesene from contract manufacturers Biomin in Piracicaba, Brazil; Antibioticos in Leon, Spain; and Tate & Lyle in Illinois, US, with a total production volume of around 600,000 liters/month.
Next year, Amyris expects additional farnesene-based production currently being constructed in Sao Paulo coming from two joint ventures — one with Paraíso Bioenergia S.A. and the other with Grupo São Martinho. Amyris’ target Biofene production volume in 2012 is around 40-50m liters/year. Just to remind readers, 85 liters of ethanol is equivalent to 50 liters of Biofene.